Key Points
- Director Luke Evnin executed a string of insider sales from Dec 31–Jan 15, totaling approximately 317,185 shares for about $188,000, including a 30,616‑share sale on Jan 14 at $0.57; his Jan 14 filing showed ownership of 2,236,055 shares after that trade.
- Werewolf Therapeutics shares opened at $0.55 and were trading down 5.7%, near a 12‑month low of $0.53 with a market cap of $26.7 million, and the street consensus rating is "Hold" with a $3.75 target.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $0.57, for a total transaction of $17,451.12. Following the sale, the director directly owned 2,236,055 shares in the company, valued at $1,274,551.35. This trade represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Luke Evnin also recently made the following trade(s):
- On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $20,577.15.
- On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total value of $23,758.90.
- On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
- On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $15,053.58.
- On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
- On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
- On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $26,494.65.
- On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
- On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
- On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
Werewolf Therapeutics Trading Down 5.7%
Shares of Werewolf Therapeutics stock opened at $0.55 on Friday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $2.38. The firm has a market capitalization of $26.74 million, a PE ratio of -0.34 and a beta of 0.77. The firm's 50-day moving average price is $0.84 and its 200 day moving average price is $1.23.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. On average, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on HOWL. Citigroup lowered Werewolf Therapeutics from a "market outperform" rating to a "market perform" rating in a research note on Friday, December 19th. HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, December 19th. Bank of America dropped their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. Wedbush downgraded Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 price target on the stock. in a report on Friday, December 19th. Finally, Zacks Research cut shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 21st. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $3.75.
View Our Latest Analysis on HOWL
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $28,000. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter valued at $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter valued at $79,000. Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics during the second quarter worth about $92,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock valued at $111,000 after buying an additional 62,414 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
